WTO-在世界各地开发和提供新冠肺炎疫苗（英文）-2020.12-34页_3mb

Summary of "Developing and Delivering COVID-19 Vaccines Around the World"

Core Content

This document provides an overview of the role of trade policy in facilitating the development and delivery of COVID-19 vaccines globally. It outlines the challenges and opportunities in the vaccine supply chain and emphasizes the importance of international cooperation, regulatory frameworks, and intellectual property (IP) management in ensuring equitable access and effective distribution.

Main Points

1. Background on Vaccines and Immunization

• Vaccines are essential for preventing and controlling infectious diseases.
• Immunization averts 2-3 million deaths annually.
• Vaccines are critical to achieving the 2030 goal of ending preventable deaths of newborns and children under 5.
• The G20 Leaders' Declaration (2020) recognizes vaccines as a global public good.

2. Vaccine Development and Production Timeline

• The genetic sequence of SARS-CoV-2 was published on 12 January 2020.
• By mid-2020, over 321 vaccine candidates were in development, with 42 in clinical evaluation and 162 in preclinical evaluation.
• Vaccine development typically takes over 10 years, but the pandemic accelerated this process.
• By end-2021, it was estimated that 2 billion doses would be distributed globally.

3. Global Vaccine Production and Distribution Capacity

• Annual production capacity for vaccines was expected to reach 610 million doses by end-2020 and over 1 billion by 2021.
• The U.S. Operation Warp Speed aimed to deliver 300 million doses by January 2021.
• CEPI estimated that 2–4 billion doses could be manufactured before the end of 2021.

4. Trade and Supply Chain Challenges

• Vaccines are biological products sensitive to environmental conditions, requiring strict temperature control and cold-chain logistics.
• Trade restrictions, export prohibitions, and limited transportation options can impede vaccine distribution.
• Over 43 WTO members and 6 non-WTO members had export restrictions on medical goods in early December 2020.

5. Regulatory Approvals and Emergency Use

• Two forms of regulatory approval are available: emergency use authorizations and standard approvals.
• Emergency use authorizations are time-limited and subject to specific conditions to ensure quality and safety.
• Examples include approvals by the UK, FDA, and EMA in late 2020.

6. Intellectual Property (IP) and Trade Considerations

• IP plays a significant role in the vaccine value chain, from R&D to manufacturing.
• Licensing is crucial for accessing raw materials and technologies needed for local production.
• Voluntary and compulsory licensing are both policy options to facilitate access.
• WTO members have used the TRIPS Agreement to apply diverse data protection policies, with some allowing public interest exceptions.

7. Importance of Cross-Border Collaboration

• The pandemic has highlighted the need for global scientific collaboration and timely exchange of data, samples, and materials.
• The WHO and other organizations have issued guidelines and frameworks to support R&D and ensure quality and safety.
• Public-private partnerships and global initiatives like COVAX are key to securing vaccine supply and affordability.

8. Logistics and Distribution

• The supply chain for vaccines requires a functional, end-to-end logistics system.
• Efficient handling, storage, and transportation are essential to maintaining vaccine quality.
• DHL and McKinsey estimated that in a stringent scenario, over 10 billion doses would need to be shipped, with 15 million deliveries in cooling boxes.

9. WTO and Other Resources for Trade Policy

• The WTO provides resources such as the TRIPS Agreement and TBT Agreement to support trade policy in the vaccine context.
• Non-exhaustive lists of relevant resources include WHO, WIPO, Gavi, and the Medicines Patent Pool.
• The WTO encourages targeted, proportionate, transparent, and temporary trade measures to promote public health.

Key Information

• Global Vaccine Demand (2018): 3.5 billion doses.
• Vaccine Shortages (2018): 69 countries reported stockouts.
• Vaccine Supply Chain Requirements:
  • Right product
  • Right quantity
  • Right condition
  • Right place
  • Right time
  • Right cost
• Vaccine Development Process:
  • R&D involves collaboration across public and private sectors.
  • Over 6,000 scientific studies and 2,262 clinical trials were conducted on COVID-19.
• Trade Restrictions:
  • 43 WTO members and 6 non-WTO members had export restrictions in early December 2020.
  • These restrictions may impact the timely and equitable distribution of vaccines.
• COVAX Initiative:
  • A global pooled procurement mechanism managed by Gavi, CEPI, and WHO.
  • Aims to distribute 2 billion doses by end-2021, with 20% allocation per country.
• Regulatory and IP Considerations:
  • Regulatory authorities must ensure quality, safety, and efficacy of vaccines.
  • Data protection and IP access rules vary across WTO members.
  • Emergency Use Listing (EUL) by WHO is a tool for assessing unlicensed vaccines in emergencies.

Conclusion

The rapid development and distribution of COVID-19 vaccines require a coordinated, transparent, and flexible approach to trade policy, IP management, and regulatory frameworks. Ensuring an effective supply chain is critical to meeting global demand and preventing preventable deaths. Cross-border collaboration, data sharing, and equitable access to medical technologies are essential to achieving these goals.